{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T15:45:55Z","timestamp":1793202355791,"version":"4.5.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100015295","name":"Rocket","doi-asserted-by":"publisher","award":["Rocket"],"award-info":[{"award-number":["Rocket"]}],"id":[{"id":"10.13039\/100015295","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Danon disease (DD) is a rare X-linked cardioskeletal myopathy caused by pathogenic mutations in lysosomal-associated membrane protein-2 (\n                      <jats:italic>LAMP2<\/jats:italic>\n                      ). It is a multisystemic disease that affects the heart, skeletal, neurologic and ophthalmic systems. With an early age of onset especially in males and no treatment for the cardiomyopathy outside of heart transplant, natural history studies have been paramount to providing clinical data for the development and advancement of disease-focused therapies. Herein we present a comprehensive, prospective study detailing both cardiac and extracardiac features of DD.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      The cohort was comprised of 8 male pediatric and 1 male young adult patient, enrolled at the University of California, San Diego. Diagnosis of DD was confirmed with a pathogenic or likely pathogenic\n                      <jats:italic>LAMP2<\/jats:italic>\n                      variants. The patients underwent serial quality of life, neuropsychological, cognitive, ophthalmological, cardiac, pulmonary, and neuromuscular assessments every 6 months for 3 years.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The mean age of the cohort at study enrollment was 11.6\u2009\u00b1\u20094.5 years. The mean age of the cohort at diagnosis was 6.5\u2009\u00b1\u20095.2 years. Quality of life: assessed through the Pediatric Cardiac Quality of Life Inventory (PCQLI) and Pediatric Quality of Life Inventory (PQLQ) reveals perceptions of poor quality of life by both patients and parents. Cognitive: Differential Ability Scales-II (DAS-II) and Vineland Adaptive Behavior Scales-3 (VABS-3) showed marked intellectual disability at baseline. Cardiac: over time, ejection fraction decreased, myocardial walls thickened, and left ventricular mass increased. Pulmonary: FVC increased over time; cardiopulmonary exercise testing (CPET) revealed decreased exercise capacity as measured by peak oxygen uptake (peak VO\n                      <jats:sub>2<\/jats:sub>\n                      max) and 6-minute walk test (6MWT). Neuromuscular: most patients in the cohort achieved maximum scores on North Star Ambulatory Assessment (NSAA), with minimal changes over 6-month follow-up; they were faster than a study of normal children during the 10-meter walk test (10MWT); they were slower than a study of normal children during time to rise and the 4-stair climb test.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Natural history studies provide an important opportunity to study rare diseases, especially when longitudinal data is available to characterize clinical changes and disease course. In the case of DD, young, male patients were found to have general deficits across quality-of-life indices and cognitive, cardiac, neuromuscular, ophthalmologic, and pulmonary functions. Stabilization or improvements in these domains may be appropriate outcomes for clinical trials to consider.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-025-04058-8","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T11:34:49Z","timestamp":1761046489000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Danon disease in male patients: a prospective natural history study to augment understanding of the phenotype"],"prefix":"10.1186","volume":"20","author":[{"given":"Tarek","family":"Khedro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Attias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Eshraghian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melina","family":"Tsotras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Margolin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaden","family":"Yassin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Silver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan","family":"Bui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shyamanga","family":"Borooah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chamindra G.","family":"Laverty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew R. G.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric D.","family":"Adler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3293-138X","authenticated-orcid":false,"given":"Kimberly N.","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,21]]},"reference":[{"key":"4058_CR1","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.jacc.2023.08.014","volume":"82","author":"KN Hong","year":"2023","unstructured":"Hong KN, Eshraghian EA, Arad M, Argir\u00f2 A, Brambatti M, Bui Q, Caspi O, de Frutos F, Greenberg B, Ho CY, et al. International consensus on differential diagnosis and management of patients with Danon disease: JACC State-of-the-Art review. J Am Coll Cardiol. 2023;82:1628\u201347. https:\/\/doi.org\/10.1016\/j.jacc.2023.08.014.","journal-title":"J Am Coll Cardiol"},{"key":"4058_CR2","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/nan.12587","volume":"46","author":"G Cenacchi","year":"2020","unstructured":"Cenacchi G, Papa V, Pegoraro V, Marozzo R, Fanin M, Angelini C. Review: Danon disease: review of natural history and recent advances. Neuropathol Appl Neurobiol. 2020;46:303\u201322. https:\/\/doi.org\/10.1111\/nan.12587.","journal-title":"Neuropathol Appl Neurobiol"},{"key":"4058_CR3","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1161\/CIRCULATIONAHA.105.546481","volume":"112","author":"Z Yang","year":"2005","unstructured":"Yang Z, McMahon CJ, Smith LR, Bersola J, Adesina AM, Breinholt JP, Kearney DL, Dreyer WJ, Denfield SW, Price JF, et al. Danon disease as an underrecognized cause of hypertrophic cardiomyopathy in children. Circulation. 2005;112:1612\u20137. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.105.546481.","journal-title":"Circulation"},{"key":"4058_CR4","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/j.amjcard.2016.06.037","volume":"118","author":"L Fu","year":"2016","unstructured":"Fu L, Luo S, Cai S, Hong W, Guo Y, Wu J, Liu T, Zhao C, Li F, Huang H, et al. Identification of LAMP2 mutations in Early-Onset Danon disease with hypertrophic cardiomyopathy by targeted Next-Generation sequencing. Am J Cardiol. 2016;118:888\u201394. https:\/\/doi.org\/10.1016\/j.amjcard.2016.06.037.","journal-title":"Am J Cardiol"},{"key":"4058_CR5","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1038\/s10038-018-0479-y","volume":"63","author":"T Hayashi","year":"2018","unstructured":"Hayashi T, Tanimoto K, Hirayama-Yamada K, Tsuda E, Ayusawa M, Nunoda S, Hosaki A, Kimura A. Genetic background of Japanese patients with pediatric hypertrophic and restrictive cardiomyopathy. J Hum Genet. 2018;63:989\u201396. https:\/\/doi.org\/10.1038\/s10038-018-0479-y.","journal-title":"J Hum Genet"},{"key":"4058_CR6","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1038\/s41436-018-0046-0","volume":"21","author":"F Mazzarotto","year":"2019","unstructured":"Mazzarotto F, Girolami F, Boschi B, Barlocco F, Tomberli A, Baldini K, Coppini R, Tanini I, Bardi S, Contini E, et al. Defining the diagnostic effectiveness of genes for inclusion in panels: the experience of two decades of genetic testing for hypertrophic cardiomyopathy at a single center. Genet Med. 2019;21:284\u201392. https:\/\/doi.org\/10.1038\/s41436-018-0046-0.","journal-title":"Genet Med"},{"key":"4058_CR7","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1136\/hrt.2003.029504","volume":"90","author":"P Charron","year":"2004","unstructured":"Charron P, Villard E, S\u00e9billon P, Lafor\u00eat P, Maisonobe T, Duboscq-Bidot L, Romero N, Drouin-Garraud V, Fr\u00e9bourg T, Richard P, et al. Danon\u2019s disease as a cause of hypertrophic cardiomyopathy: a systematic survey. Heart. 2004;90:842\u20136. https:\/\/doi.org\/10.1136\/hrt.2003.029504.","journal-title":"Heart"},{"key":"4058_CR8","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1056\/NEJMoa033349","volume":"352","author":"M Arad","year":"2005","unstructured":"Arad M, Maron BJ, Gorham JM, Johnson WH Jr, Saul JP, Perez-Atayde AR, Spirito P, Wright GB, Kanter RJ, Seidman CE, et al. Glycogen storage diseases presenting as hypertrophic cardiomyopathy. N Engl J Med. 2005;352:362\u201372. https:\/\/doi.org\/10.1056\/NEJMoa033349.","journal-title":"N Engl J Med"},{"key":"4058_CR9","unstructured":"Danon Disease. 2020. https:\/\/rocketpharma.com\/clinical-trials\/danon-disease\/"},{"key":"4058_CR10","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1542\/peds.2009-2973","volume":"126","author":"BS Marino","year":"2010","unstructured":"Marino BS, Tomlinson RS, Wernovsky G, Drotar D, Newburger JW, Mahony L, Mussatto K, Tong E, Cohen M, Andersen C, et al. Validation of the pediatric cardiac quality of life inventory. Pediatrics. 2010;126:498\u2013508. https:\/\/doi.org\/10.1542\/peds.2009-2973.","journal-title":"Pediatrics"},{"key":"4058_CR11","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1097\/00005650-199902000-00003","volume":"37","author":"JW Varni","year":"1999","unstructured":"Varni JW, Seid M, Rode CA. The PedsQL\u2122: measurement model for the pediatric quality of life inventory. Med Care. 1999;37:126\u201339.","journal-title":"Med Care"},{"key":"4058_CR12","doi-asserted-by":"publisher","unstructured":"Varni J.W., Burwinkle T.M., Seid M., Skarr D. The PedsQL 4.0 as a pediatric population health measure: feasibility, reliability, and validity. Ambul Pediatr. 2003;3:329\u201341. https:\/\/doi.org\/10.1367\/1539-4409(2003)003%3C0329:tpaapp%3E2.0.co;2.","DOI":"10.1367\/1539-4409(2003)003%3C0329:tpaapp%3E2.0.co;2"},{"key":"4058_CR13","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1007\/s00246-014-1042-z","volume":"36","author":"MR Friess","year":"2015","unstructured":"Friess MR, Marino BS, Cassedy A, Wilmot I, Jefferies JL, Lorts A. Health-related quality of life assessment in children followed in a cardiomyopathy clinic. Pediatr Cardiol. 2015;36:516\u201323. https:\/\/doi.org\/10.1007\/s00246-014-1042-z.","journal-title":"Pediatr Cardiol"},{"key":"4058_CR14","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1017\/S1047951115001717","volume":"26","author":"A Spanaki","year":"2016","unstructured":"Spanaki A, O\u2019Curry S, Winter-Beatty J, Mead-Regan S, Hawkins K, English J, Head C, Ridout D, Tome-Esteban MT, Elliott P, et al. Psychosocial adjustment and quality of life in children undergoing screening in a specialist paediatric hypertrophic cardiomyopathy clinic. Cardiol Young. 2016;26:961\u20137. https:\/\/doi.org\/10.1017\/S1047951115001717.","journal-title":"Cardiol Young"},{"key":"4058_CR15","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1080\/09297049.2015.1020775","volume":"22","author":"C Farmer","year":"2016","unstructured":"Farmer C, Golden C, Thurm A. Concurrent validity of the differential ability scales, second edition with the Mullen scales of early learning in young children with and without neurodevelopmental disorders. Child Neuropsychol. 2016;22:556\u201369. https:\/\/doi.org\/10.1080\/09297049.2015.1020775.","journal-title":"Child Neuropsychol"},{"key":"4058_CR16","volume-title":"Vineland adaptive behavior Scales\u2013Third edition: manual","author":"SS Sparrow","year":"2016","unstructured":"Sparrow SS, Cicchetti DV, Saulnier CA. Vineland adaptive behavior Scales\u2013Third edition: manual. Bloomington, MN: Pearson; 2016."},{"key":"4058_CR17","doi-asserted-by":"publisher","DOI":"10.1111\/jir.13094","author":"RM Pollak","year":"2023","unstructured":"Pollak RM, Burrell TL, Cubells JF, Klaiman C, Murphy MM, Saulnier CA, Walker EF, White SP, Mulle JG. Adaptive behaviour deficits in individuals with 3q29 deletion syndrome. J Intellect Disabil Res. 2023. https:\/\/doi.org\/10.1111\/jir.13094.","journal-title":"J Intellect Disabil Res"},{"key":"4058_CR18","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/1471-2377-12-91","volume":"12","author":"A Lerario","year":"2012","unstructured":"Lerario A, Bonfiglio S, Sormani M, Tettamanti A, Marktel S, Napolitano S, Previtali S, Scarlato M, Natali-Sora M, Mercuri E, et al. Quantitative muscle strength assessment in Duchenne muscular dystrophy: longitudinal study and correlation with functional measures. BMC Neurol. 2012;12:91. https:\/\/doi.org\/10.1186\/1471-2377-12-91.","journal-title":"BMC Neurol"},{"key":"4058_CR19","doi-asserted-by":"publisher","first-page":"e0283669","DOI":"10.1371\/journal.pone.0283669","volume":"18","author":"V Ayyar Gupta","year":"2023","unstructured":"Ayyar Gupta V, Pitchforth JM, Domingos J, Ridout D, Iodice M, Rye C, Chesshyre M, Wolfe A, Selby V, Mayhew A, et al. Determining minimal clinically important differences in the North star ambulatory assessment (NSAA) for patients with Duchenne muscular dystrophy. PLoS ONE. 2023;18:e0283669. https:\/\/doi.org\/10.1371\/journal.pone.0283669.","journal-title":"PLoS ONE"},{"key":"4058_CR20","doi-asserted-by":"publisher","first-page":"264","DOI":"10.4103\/aca.aca_35_21","volume":"25","author":"S Chatterjee","year":"2022","unstructured":"Chatterjee S, Mukherjee S, Rani N, Kumar P, Kumar P, Sarkar A. Assessment of cardiac function in children by strain imaging and its correlation with conventional echocardiographic parameter. Ann Card Anaesth. 2022;25:264\u20139. https:\/\/doi.org\/10.4103\/aca.aca_35_21.","journal-title":"Ann Card Anaesth"},{"key":"4058_CR21","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1002\/cncr.10428","volume":"94","author":"JW Varni","year":"2002","unstructured":"Varni JW, Burwinkle TM, Katz ER, Meeske K, Dickinson P. The PedsQL in pediatric cancer: reliability and validity of the pediatric quality of life inventory generic core Scales, multidimensional fatigue Scale, and cancer module. Cancer. 2002;94:2090\u2013106. https:\/\/doi.org\/10.1002\/cncr.10428.","journal-title":"Cancer"},{"key":"4058_CR22","doi-asserted-by":"publisher","first-page":"107599","DOI":"10.1016\/j.dib.2021.107599","volume":"39","author":"M Smyth","year":"2021","unstructured":"Smyth M, Jacobson K. Pediatric quality of life inventorytm version 4.0 short form generic core scale across pediatric populations review data. Data Brief. 2021;39:107599. https:\/\/doi.org\/10.1016\/j.dib.2021.107599.","journal-title":"Data Brief"},{"key":"4058_CR23","volume-title":"Danon disease","author":"MRG Taylor","year":"2020","unstructured":"Taylor MRG, Adler ED. Danon disease. Seattle: University of Washington; 2020."},{"key":"4058_CR24","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1002\/ajmg.a.38320","volume":"173","author":"M Yardeni","year":"2017","unstructured":"Yardeni M, Weisman O, Mandel H, Weinberger R, Quarta G, Salazar-Mendiguch\u00eda J, Garcia-Pavia P, Lobato-Rodr\u00edguez MJ, Simon LF, Dov F, et al. Psychiatric and cognitive characteristics of individuals with Danon disease (LAMP2 gene mutation). Am J Med Genet A. 2017;173:2461\u20136. https:\/\/doi.org\/10.1002\/ajmg.a.38320.","journal-title":"Am J Med Genet A"},{"key":"4058_CR25","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1186\/s13023-023-02805-3","volume":"18","author":"J Muenzer","year":"2023","unstructured":"Muenzer J, Burton BK, Amartino HM, Harmatz PR, Guti\u00e9rrez-Solana LG, Ruiz-Garcia M, Wu Y, Merberg D, Alexanderian D, Jones SA. Neurodevelopmental status and adaptive behavior of pediatric patients with mucopolysaccharidosis II: a longitudinal observational study. Orphanet J Rare Dis. 2023;18:357. https:\/\/doi.org\/10.1186\/s13023-023-02805-3.","journal-title":"Orphanet J Rare Dis"},{"key":"4058_CR26","doi-asserted-by":"publisher","unstructured":"Crotty K, Baron IS. Differential ability scales (DAS and DAS-II). In: Kreutzer JS, DeLuca J, Caplan B, editors. Encyclopedia of clinical neuropsychology. Springer New York; 2011. pp. 839\u201341. https:\/\/doi.org\/10.1007\/978-0-387-79948-3_1541.","DOI":"10.1007\/978-0-387-79948-3_1541"},{"key":"4058_CR27","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/jir.12691","volume":"64","author":"C Farmer","year":"2020","unstructured":"Farmer C, Adedipe D, Bal VH, Chlebowski C, Thurm A. Concordance of the vineland adaptive behavior Scales, second and third editions. J Intellect Disabil Res. 2020;64:18\u201326. https:\/\/doi.org\/10.1111\/jir.12691.","journal-title":"J Intellect Disabil Res"},{"key":"4058_CR28","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/aos.14478","volume":"99","author":"B Kousal","year":"2021","unstructured":"Kousal B, Majer F, Vlaskova H, Dvorakova L, Piherova L, Meliska M, Langrova H, Palecek T, Kubanek M, Krebsova A, et al. Pigmentary retinopathy can indicate the presence of pathogenic LAMP2 variants even in somatic mosaic carriers with no additional signs of Danon disease. Acta Ophthalmol. 2021;99:61\u20138. https:\/\/doi.org\/10.1111\/aos.14478.","journal-title":"Acta Ophthalmol"},{"key":"4058_CR29","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1161\/CIRCHEARTFAILURE.114.001105","volume":"7","author":"RS D\u2019souza","year":"2014","unstructured":"D\u2019souza RS, Levandowski C, Slavov D, Graw SL, Allen LA, Adler E, Mestroni L, Taylor MRG. Danon disease: clinical features, evaluation, and management. Circ Heart Fail. 2014;7:843\u20139. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.114.001105.","journal-title":"Circ Heart Fail"},{"key":"4058_CR30","doi-asserted-by":"publisher","first-page":"1159576","DOI":"10.3389\/fcvm.2023.1159576","volume":"10","author":"X Liu","year":"2023","unstructured":"Liu X, Zhai N, Wang X, Wang J, Jiang M, Sun Z, Chen Y, Xu J, Cui Y, Li L. Cardiovascular magnetic resonance findings in Danon disease: a case series of a family. Front Cardiovasc Med. 2023;10:1159576. https:\/\/doi.org\/10.3389\/fcvm.2023.1159576.","journal-title":"Front Cardiovasc Med"},{"key":"4058_CR31","doi-asserted-by":"publisher","first-page":"712e1","DOI":"10.1016\/j.crad.2020.04.012","volume":"75","author":"J He","year":"2020","unstructured":"He J, Xu J, Chen L, Ji K, Fan X, Zhao S, Lu M. Clinical features and cardiovascular magnetic resonance characteristics in Danon disease. Clin Radiol. 2020;75:712e1. https:\/\/doi.org\/10.1016\/j.crad.2020.04.012.","journal-title":"Clin Radiol"},{"key":"4058_CR32","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.nmd.2015.11.009","volume":"26","author":"EM Johnson","year":"2016","unstructured":"Johnson EM, Roberts M, Mozaffar T, Young P, Quartel A, Berger KI. Pulmonary function tests (maximum inspiratory pressure, maximum expiratory pressure, vital capacity, forced vital capacity) predict ventilator use in late-onset Pompe disease. Neuromuscul Disord. 2016;26:136\u201345. https:\/\/doi.org\/10.1016\/j.nmd.2015.11.009.","journal-title":"Neuromuscul Disord"},{"key":"4058_CR33","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1007\/s00415-021-10409-9","volume":"268","author":"K Gutschmidt","year":"2021","unstructured":"Gutschmidt K, Musumeci O, D\u00edaz-Manera J, Chien Y-H, Knop KC, Wenninger S, Montagnese F, Pugliese A, Tavilla G, Alonso-P\u00e9rez J, et al. STIG study: real-world data of long-term outcomes of adults with Pompe disease under enzyme replacement therapy with alglucosidase Alfa. J Neurol. 2021;268:2482\u201392. https:\/\/doi.org\/10.1007\/s00415-021-10409-9.","journal-title":"J Neurol"},{"key":"4058_CR34","doi-asserted-by":"publisher","first-page":"ii28","DOI":"10.1093\/eurjpc\/zwad216","volume":"30","author":"E Salvioni","year":"2023","unstructured":"Salvioni E, Bonomi A, Magr\u00ec D, Merlo M, Pezzuto B, Chiesa M, Mapelli M, Baracchini N, Sinagra G, Piepoli M, et al. The cardiopulmonary exercise test in the prognostic evaluation of patients with heart failure and cardiomyopathies: the long history of making a one-size-fits-all suit. Eur J Prev Cardiol. 2023;30:ii28\u201333. https:\/\/doi.org\/10.1093\/eurjpc\/zwad216.","journal-title":"Eur J Prev Cardiol"},{"key":"4058_CR35","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1136\/hrt.2007.121558","volume":"83","author":"K Albouaini","year":"2007","unstructured":"Albouaini K, Egred M, Alahmar A, Wright DJ. Cardiopulmonary exercise testing and its application. Postgrad Med J. 2007;83:675\u201382. https:\/\/doi.org\/10.1136\/hrt.2007.121558.","journal-title":"Postgrad Med J"},{"key":"4058_CR36","doi-asserted-by":"publisher","first-page":"426","DOI":"10.2223\/JPED.1533","volume":"82","author":"AN Rodrigues","year":"2006","unstructured":"Rodrigues AN, Perez AJ, Carletti L, Bissoli NS, Abreu GR. Maximum oxygen uptake in adolescents as measured by cardiopulmonary exercise testing: a classification proposal. J Pediatr. 2006;82:426\u201330. https:\/\/doi.org\/10.2223\/JPED.1533.","journal-title":"J Pediatr"},{"key":"4058_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40798-023-00622-3","volume":"9","author":"P Amedro","year":"2023","unstructured":"Amedro P, Matecki S, Pereira dos Santos T, Guillaumont S, Rhodes J, Yin SM, Hager A, Hock J, De La Villeon G, Moreau J, et al. Reference values of cardiopulmonary exercise test parameters in the contemporary paediatric population. Sports Med - Open. 2023;9:1\u201312. https:\/\/doi.org\/10.1186\/s40798-023-00622-3.","journal-title":"Sports Med - Open"},{"key":"4058_CR38","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1152\/japplphysiol.00520.2020","volume":"129","author":"A Gavotto","year":"2020","unstructured":"Gavotto A, Huguet H, Picot M-C, Guillaumont S, Matecki S, Amedro P. The V\u0307e\/V\u0307co2 slope: a useful tool to evaluate the physiological status of children with congenital heart disease. J Appl Physiol. 2020;129:1102\u201310. https:\/\/doi.org\/10.1152\/japplphysiol.00520.2020.","journal-title":"J Appl Physiol"},{"key":"4058_CR39","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/1471-2466-13-49","volume":"13","author":"S Ulrich","year":"2013","unstructured":"Ulrich S, Hildenbrand FF, Treder U, Fischler M, Keusch S, Speich R, Fasnacht M. Reference values for the 6-minute walk test in healthy children and adolescents in Switzerland. BMC Pulm Med. 2013;13:49. https:\/\/doi.org\/10.1186\/1471-2466-13-49.","journal-title":"BMC Pulm Med"},{"key":"4058_CR40","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1183\/09031936.05.00134904","volume":"25","author":"AM Li","year":"2005","unstructured":"Li AM, Yin J, Yu CCW, Tsang T, So HK, Wong E, Chan D, Hon EKL, Sung R. The six-minute walk test in healthy children: reliability and validity. Eur Respir J. 2005;25:1057\u201360. https:\/\/doi.org\/10.1183\/09031936.05.00134904.","journal-title":"Eur Respir J"},{"key":"4058_CR41","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s00246-016-1536-y","volume":"38","author":"SL den Boer","year":"2017","unstructured":"den Boer SL, Flipse DHK, van der Meulen MH, Backx APCM, du Marchie Sarvaas GJ, Ten Harkel ADJ, van Iperen GG, Rammeloo LAJ, Tanke RB, Helbing WA, et al. Six-Minute walk test as a predictor for outcome in children with dilated cardiomyopathy and chronic stable heart failure. Pediatr Cardiol. 2017;38:465\u201371. https:\/\/doi.org\/10.1007\/s00246-016-1536-y.","journal-title":"Pediatr Cardiol"},{"key":"4058_CR42","doi-asserted-by":"publisher","first-page":"e0221097","DOI":"10.1371\/journal.pone.0221097","volume":"14","author":"F Muntoni","year":"2019","unstructured":"Muntoni F, Domingos J, Manzur AY, Mayhew A, Guglieri M, NorthStar Network UK, Sajeev G, Signorovitch J, Ward SJ. Categorising trajectories and individual item changes of the North star ambulatory assessment in patients with Duchenne muscular dystrophy. PLoS ONE. 2019;14:e0221097. https:\/\/doi.org\/10.1371\/journal.pone.0221097.","journal-title":"PLoS ONE"},{"key":"4058_CR43","doi-asserted-by":"publisher","first-page":"153","DOI":"10.3233\/JND-230159","volume":"11","author":"G Stimpson","year":"2024","unstructured":"Stimpson G, Ridout D, Wolfe A, Milev E, O\u2019Reilly E, Manzur A, Sarkozy A, Muntoni F, Cole TJ, Baranello G, et al. Quantifying variability in motor function in Duchenne muscular dystrophy: UK centiles for the NorthStar ambulatory Assessment, 10 m walk run velocity and rise from floor velocity in GC treated boys. J Neuromuscul Dis. 2024;11:153\u201366. https:\/\/doi.org\/10.3233\/JND-230159.","journal-title":"J Neuromuscul Dis"},{"key":"4058_CR44","doi-asserted-by":"publisher","first-page":"950651","DOI":"10.3389\/fphar.2022.950651","volume":"13","author":"J Deng","year":"2022","unstructured":"Deng J, Zhang J, Shi K, Liu Z. Drug development progress in Duchenne muscular dystrophy. Front Pharmacol. 2022;13:950651. https:\/\/doi.org\/10.3389\/fphar.2022.950651.","journal-title":"Front Pharmacol"},{"key":"4058_CR45","first-page":"4","volume":"23","author":"DC Schorling","year":"2023","unstructured":"Schorling DC, Rawer R, Kuhlmann I, M\u00fcller C, Pechmann A, Kirschner J. Mechanographic analysis of the timed 4 stair climb test - methodology and reference data of healthy children and adolescents. J Musculoskelet Neuronal Interact. 2023;23:4\u201325.","journal-title":"J Musculoskelet Neuronal Interact"},{"key":"4058_CR46","doi-asserted-by":"publisher","unstructured":"de Baptista CRJA, Vicente AM, Souza MA, Cardoso J, Ramalho VM, Mattiello-Sverzut AC. Methods of 10-meter walk test and repercussions for reliability obtained in typically developing children. Rehabil Res Pract. 2020;2020(4209812). https:\/\/doi.org\/10.1155\/2020\/4209812.","DOI":"10.1155\/2020\/4209812"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-04058-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-04058-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-04058-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T12:40:16Z","timestamp":1781613616000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13023-025-04058-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,21]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4058"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-04058-8","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,21]]},"assertion":[{"value":"21 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Include a statement on ethics approval and consent (even where the need for approval was waived). Include the name of the ethics committee that approved the study and the committee\u2019s reference number if appropriate.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"EDA declares that he is consulting for Abiomed, Novartis, Abbott, Ionis Pharmaceuticals, Sana Biotechnology, Medtronic, Lexeo Pharmaceuticals, Cytokinetics, and Endotronics. He also reports Papillion Therapeutics (Founder and Board Member) and ResQ Pharmaceuticals (Scientific Advisory Board); he is a Shareholder for Rocket Pharmaceuticals; and he was an expert witness for AstraZeneca. QB is a consultant for EcoR1 and Lexeo Therapeutics. CGL declares that she is consulting for Sarepta Therapeutics, Dyne Therapeutics, Avidity Biosciences, Catalyst, Biogen, and Novartis. KNH, TK, ES, JA, SY, MRGT declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"530"}}